Page 5 - Johnson & Johnson

Wall Street set for higher open on J&J vaccine cheer, stimulus optimism

President Joe Biden scored his first legislative win as the House of Representatives passed his $1.9 trillion coronavirus relief package early Saturday

US CDC panel endorses emergency use of Johnson & Johnson Covid-19 vaccine

US' Centers for Disease Control and Prevention (CDC) advisory committee on Sunday has voted to recommend that Johnson & Johnson's COVID-19 vaccine can be given to people ages 18 and older in the United States.The announcement by CDC Director Rochelle Walensky will allow vaccinations to begin as soon as the doses are received, The Hill reported. The Advisory Committee on Immunization Practices voted 12-0, with one recusal, to recommend the use of the Johnson & Johnson vaccine.Walensky called the decision "another milestone toward an end to the pandemic." This comes a day after the Food and Drug Administration (FDA) announced that it had approved Janssen's single-dose COVID-19 Vaccine for emergency use in the US in individuals 18 years of age and older."This vaccine is also another important tool in our toolbox to equitably vaccinate as many people as possible, as quickly as possible," Walensky said in a statement."As a one-dose vaccine, people do not have to return for a ...

J&J's 1-dose shot cleared, giving US 3rd Covid-19 vaccine

The US is getting a third vaccine to prevent COVID-19, as the Food and Drug Administration on Saturday cleared a Johnson & Johnson shot that works with just one dose instead of two. Health experts are anxiously awaiting a one-and-done option to help speed vaccinations, as they race against a virus that already has killed more than 510,000 people in the US and is mutating in increasingly worrisome ways. The FDA said J&J's vaccine offers strong protection against what matters most: serious illness, hospitalizations and death. One dose was 85% protective against the most severe COVID-19 illness, in a massive study that spanned three continents protection that remained strong even in countries such as South Africa, where the variants of most concern are spreading. The more vaccines that have high efficacy that we can get into play, the better, Dr. Anthony Fauci, the top US infectious disease expert, said ahead of the FDA's ruling. Shipments of a few million doses to be divided ...

Johnson & Johnson's Covid-19 vaccine on track for US emergency approval

US regulators are working "rapidly" to finalise emergency use authorisation for a Johnson & Johnson vaccine which is on track to become America's third shot against the coronavirus pandemic which has killed 509,000 people in the last 12 months alone - the country's deadliest year.

FDA advisory panel to review J&J Covid-19 vaccine with thumbs up expected

(Reuters) - A panel of expert advisers to the U.S. Food and Drug Administration began a meeting to discuss Johnson & Johnson's one-dose COVID-19 vaccine on Friday, setting the stage for a possible emergency use authorization as early as this week.

FDA says single-dose shot from J&J vaccine prevents severe Covid-19

Johnson & Johnson's single-dose vaccine offers strong protection against severe COVID-19, according to an analysis released by US regulators that sets the stage for a final decision on a new and easier-to-use shot to help tame the pandemic. The long-anticipated shot could offer the nation a third vaccine option and help speed vaccinations by requiring just one dose instead of two. Food and Drug Administration scientists on Wednesday confirmed that overall the vaccine is about 66% effective at preventing moderate to severe COVID-19, and about 85% effective against the most serious illness. The agency also said J&J's shot is safe. The analysis is just one step in the FDA's evaluation. On Friday, the agency's independent advisers will debate if the evidence is strong enough to recommend the shot. With that advice, the FDA is expected to make a final decision within days. The COVID-19 death toll in the US topped 500,000 this week, and the vaccination drive has been slower than ...

Johnson & Johnson's one-shot Covid-19 vaccine effective, safe: FDA staff

(Reuters) - Johnson & Johnson's one-shot COVID-19 vaccine appeared safe and effective in trials, U.S. Food and Drug Administration (FDA) staff said in documents published on Wednesday, paving the way for its approval for emergency use.

US: Johnson & Johnson says can provide 20 million coronavirus vaccine doses

Drugmaker Johnson & Johnson says it will be able to provide 20 million US doses of its single-shot COVID-19 vaccine by the end of March, assuming it gets the greenlight from federal regulators. J&J disclosed the figure in written testimony ahead of a Congressional hearing on Tuesday looking at the country's vaccine supply. White House officials cautioned last week that initial supplies of J&J's vaccine would be limited. The company reiterated that it will have capacity to provide 100 million vaccine doses to the US by the end of June. That supply will help government officials reach the goal of having enough injections to vaccinate most adult Americans later this year. On a global scale the company aims to produce 1 billion doses this year. US health regulators are still reviewing the safety and effectiveness of the shot and a decision to allow its emergency use is expected later this week. J&J's vaccine would be the first in the US that requires only a single ...

J&J applies to WHO for emergency use listing of Covid-19 vaccine

J&J said an emergency use listing is a prerequisite for supplying vaccines to the COVAX vaccine program, co-led by WHO, which aims to deliver doses to poor and middle-income countries

J&J's vaccine implementation study in South Africa gets regulator nod

South Africa has yet to launch its Covid-19 vaccination programme and the government has decided to go with the J&J dose

J&J says vaccine offers 100% protection against coronavirus deaths

In the more than 44,000-person study, the vaccine prevented 66 per cent of moderate to severe cases of Covid-19

Johnson & Johnson expects Covid-19 vaccine data next week: Report

The company forecast 2021 profit well above Wall Street estimates, and its shares rose 3.4% to $171.55

S&P 500 scales new high on upbeat corporate earnings; GE jumps 8%

The Dow Jones Industrial Average rose 8.5 points, or 0.03%, at the open to 30968.55

Johnson & Johnson's one shot Covid vaccine grants lasting response in trial

More than 90% of participants made immune proteins, called neutralizing antibodies, within 29 days after receiving the shot, according to the report

Delhi HC postpones hearing on pleas against anti-profiteering to Feb 15

Petitions were listed today before the division bench for hearing, but due to elevation of one of the judges, a change in the roster is expected

COVAX gains access to 2 billion doses of vaccines for 190 member economies

First deliveries are expected to begin in the first quarter of 2021 depending upon regulatory approvals and readiness of countries for delivery

J&J has applied to South Africa for registering coronavirus vaccine

The US firm's vaccine candidate is one of at least four Covid vaccines being trialled in South Africa, along with candidates being developed by Novavax, AstraZeneca and Pfizer

Nasdaq at record high; Dow, S&P 500 lifted by J&J's vaccine result hopes

(Reuters) - The S&P 500 and the Dow reversed course to rise on Tuesday, led by drugmaker Johnson & Johnson following encouraging news on its COVID-19 vaccine, while the Nasdaq hit a record high.

J&J expects data for US authorisation of Covid-19 vaccine by February

The company paused the trial in October because of a serious medical event in one participant and resumed after getting the green light from an independent safety panel.

Covid19: Airline pilots under stress, J&J vaccine trials in youths & more

On the vaccine front, Johnson & Johnson plans to start testing its experimental Covid-19 vaccine in youths aged 12 to 18 as soon as possible